Eden Research plc Admission to the US OTC Market (5901P)

TIDMEDEN

RNS Number : 5901P

Eden Research plc

20 October 2021

20(th) October 2021

Eden Research

("Eden" or "the Company")

Admission to the US OTC Market

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in global crop protection, animal health and consumer products industries, is pleased to announce its shares will be traded on the U.S. OTC market.

Eden's shares will trade on the U.S. OTCQB Venture Market under the ticker EDNSF and will commence trading on 20(th) October 2021. The OTCQB listing will provide U.S. investors with the ability to trade in the Company's ordinary shares in U.S. dollars and during U.S. market hours, thus allowing this group access to transact in Eden shares.

The U.S. capital market represents an exciting and untapped opportunity for Eden to diversify its shareholder base with a strong appeal to its active investor community. Eden is supporting this listing on OTCQB with new investor relations activity in the U.S. aimed at creating visibility for U.S. investors, broadening the Company's shareholder base and improving stock liquidity.

Sean Smith, Chief Executive Officer of Eden Research plc, commented:

"Our OTCQB listing marks another important milestone for Eden as we seek to become a leader in biocontrol products. We are currently in the process of securing regulatory approval for Eden's flagship products - Mevalone(R) and Cedroz(TM) - in the U.S., which will present significant market opportunities for the business in that region.

The U.S. has one of the largest organic food markets in the world, and its ongoing growth presents a significant opportunity for biopesticide market participants. As the only AIM-quoted company focused on biopesticides, we believe that Eden offers a unique proposition for U.S.-based investors seeking to participate in the rapid growth and promising future of sustainable agriculture."

Eden was sponsored for its OTCQB listing by B. Riley Financial, a qualified third-party firm responsible for providing guidance on OTCQB requirements and recommending membership. Trading on the U.S. OTC market has no impact on existing Eden ordinary shares trading on the AIM market of the London Stock Exchange and no new ordinary shares will be issued as part of the cross-trade. Eden will continue to rely on the announcements and disclosures it makes to the London Stock Exchange and will have no Sarbanes-Oxley or SEC reporting requirements.

For further information contact:

 
 Eden Research plc                                    www.edenresearch.com 
 Sean Smith 
  Alex Abrey                                                 01285 359 555 
 
 Cenkos Securities plc (Nominated advisor 
  and broker) 
 Giles Balleny / Camilla Hume / Mark Connelly 
  (corporate finance) 
  Michael Johnson (sales)                                    020 7397 8900 
 
 Hawthorn Advisors (Financial PR) 
 Victoria Ainsworth                              eden@hawthornadvisors.com 
  Johanna Pemberton

Notes to Editors:

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market:

Mevalone (R) is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

Cedroz (TM) is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

Eden's Sustaine(R) encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

   For more information about Eden, please visit:   www.edenresearch.com  .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSMZMMGRLZGMZM

(END) Dow Jones Newswires

October 20, 2021 02:00 ET (06:00 GMT)

Eden Research (AQSE:EDEN.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024